News

Dermatology Times is looking back on the top stories in dermatology from the month of January.

Learn more about the in-depth topics covered in the January 2024 print issue of Dermatology Times.

Positive results in preclinical animal trials of DPT0218 may lead to advances in clinical treatment of autoimmune diseases.

People with vitiligo face a higher risk of retinal detachment, according to a study in Taiwan.

Functional magnetic resonance imaging response was utilized to test motor, somatosensory association cortex, perception, and sensory integration processing in a recent study.

Among the many sessions to be held at the IMCAS World Congress 2024 in Paris, France, several Dermatology Times Editorial Advisory Board members are preparing to share their knowledge and insights.

Learn more about the in-depth topics covered in the January 2024 topical treatments for vitiligo supplement of Dermatology Times.

Patients with chronic spontaneous urticaria saw improvement in itch and hive severity when dupilumab was added to their antihistamines in a 24-week study.

An immunosuppressed patient with refractory plantar warts showed improvement following cantharidinpodophyllotoxin-salicylic acid (CPS) monotherapy.

The Centers for Medicare & Medicaid Services has issued a permanent J-code for the first and only FDA-approved treatment for molluscum contagiosum.

Marcelo Bigal, MD, PhD, discusses VENT-03's potential as a small molecule therapeutic in dermatology, among other fields.

Topical antifungals, whether FDA-approved or available over-the-counter, exhibited more effective penetration through cellulose disks than cadaver nails.

Let us know if you plan to attend IMCAS World Congress 2024.

ICYMI, this week we had news about the completion of LEO Pharma's acquisition of Timber Pharmaceuticals, research pointing to melanoma overdiagnosis in White patients, artificial intelligence in skin cancer detection, and more.

The novel nanofiber-based system holds promise for future nanotech applications in health care, researchers claim.

A population-based study found a 63% increase in isotretinoin use in the years 2004 to 2019, and an increase in isotretinoin-exposed pregnancies as well.

So far, 2024 is shaping up to be just as busy as 2023 with new dermatology innovations, approvals, and data. Review what's still to come in 2024.

A poster analyzing the BRAVE-AA study population was presented at Maui Derm Hawaii 2024.

A patient's social media post has gone viral and has been seen by thousands. Dr Derm is concerned this malicious act may ruin his career. What can he do?

A poster from Maui Derm Hawaii revealed an even more significant disparity than researchers anticipated.

Patients with moderate to severe AD gave their opinions in a survey on treatment options and their tradeoffs. Itch control topped the list of patient concerns.

In this week’s Pointers With Portela, the 208SkinDoc reviews various treatment methods for permanent wart removal.

This article delves into 5 critical areas that dermatologists should focus on for a comprehensive 2024 report card.

Researchers from Pyeongchon, Korea, argue that evidence points to the need for a change in the terminology of "freckling," according to a poster from Maui Derm Hawaii.

A poster presented at Maui Derm Hawaii delved into the efficacy and safety of trifarotene 50µg/g cream in acne vulgaris and PIH.

In a recent Dermatology Times Case-Based Roundtable Meeting, Tina Bhutani, MD, MAS, shared intriguing cases and insights about atopic dermatitis treatment challenges faced by patients with different lifestyles and hobbies.

Investigators explained how the trial is structured to inhibit facial sebum production and inflammation among nearly 500 study participants.

Online patient recruitment methods were effective in a proof-of-concept trial involving patients with low-grade AK.

Click here to answer this week's poll.

Advancements in assistance from artificial intelligence include ambient listening to take notes during physician and patient conversations.